Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Clin Invest ; 130(7): 3848-3864, 2020 07 01.
Article in English | MEDLINE | ID: mdl-32315290

ABSTRACT

Cancer cells can develop a strong addiction to discrete molecular regulators, which control the aberrant gene expression programs that drive and maintain the cancer phenotype. Here, we report the identification of the RNA-binding protein HuR/ELAVL1 as a central oncogenic driver for malignant peripheral nerve sheath tumors (MPNSTs), which are highly aggressive sarcomas that originate from cells of the Schwann cell lineage. HuR was found to be highly elevated and bound to a multitude of cancer-associated transcripts in human MPNST samples. Accordingly, genetic and pharmacological inhibition of HuR had potent cytostatic and cytotoxic effects on tumor growth, and strongly suppressed metastatic capacity in vivo. Importantly, we linked the profound tumorigenic function of HuR to its ability to simultaneously regulate multiple essential oncogenic pathways in MPNST cells, including the Wnt/ß-catenin, YAP/TAZ, RB/E2F, and BET pathways, which converge on key transcriptional networks. Given the exceptional dependency of MPNST cells on HuR for survival, proliferation, and dissemination, we propose that HuR represents a promising therapeutic target for MPNST treatment.


Subject(s)
Carcinogenesis/metabolism , Cell Proliferation , ELAV-Like Protein 1/metabolism , Neoplasm Proteins/metabolism , Nerve Sheath Neoplasms/metabolism , Signal Transduction , Animals , Carcinogenesis/genetics , Carcinogenesis/pathology , Cell Line, Tumor , ELAV-Like Protein 1/genetics , Humans , Mice , Neoplasm Metastasis , Neoplasm Proteins/genetics , Nerve Sheath Neoplasms/genetics , Nerve Sheath Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...